OptiBiotix Health

OPTI · AIM · Health Care · mcap £5.8m · 5.7p 1 open situation →

EV: £2.8m
EV / EBIT: –
Net cash: £989k
FCF yield: -29.3%
Revenue: £1.3m
Share price 1y: −32%
Insiders 12m: bought £10k
Next report: around 27 May

Beta Briefing, track record and signals & risks are not ready for OptiBiotix Health yet.

We follow 960 UK small caps and every one of their announcements – often hundreds per company. 101 companies are already wired into a briefing: browse them.

Timeline · every situation

dots = announcements

2026 Cost reduction and commercial sustainability plan

Open · 1

Turnaround plan with targets

Cost reduction and commercial sustainability plan

Cost cuts delivering in H1; more due H2

Since April 2026 the company has shifted to commercial sustainability, targeting £500-600k of annual savings, and a May share sale extended runway into H1 2027. H1 2026 shows the cuts working: selling costs down 69.5%, operating costs down 12.2%, China trading partner suspended. Further savings are expected in H2 as one-offs drop out.

Operating costs: £1.01m, down 12.2% (H1 2025: £1.15m), excluding share-based payments, depreciation and amortisation
Selling costs: £76k, down 69.5% (H1 2025: £249k)
China: Trading partner suspended; no ongoing cost in H2 2026
Cash: £0.99m at 30 June 2026, no debt
Next milestone: Further H2 2026 cost improvements as one-off H1 costs do not recur

Next: H2 2026 cost improvements as one-off H1 costs fall away

17 Sep 2026 Cost cuts delivering in H1; more due H2
1 May 2026 Cost cuts under way; runway extended by share sale
1 Apr 2026 Cost cuts under way; unit P&Ls being built

Open the full view – chart and every step →

Company filings. Not investment advice.